HGH (Somatotropin)
Real growth hormone in a daily shot: life-changing for the few who truly lack it, oversold to everyone else.
- What it is
- A man-made copy of your own growth hormone
- Is it FDA-approved?
- Yes, for specific medical conditions
- How strong is the proof?
- Strong for those conditions; weak for anti-aging
- How you take it
- A small shot under the skin, every day
- Typical result
- Helps people with a real deficiency; not for healthy adults
- Biggest catch
- Very pricey, sports-banned, and the anti-aging claim isn't proven
Any word with a dotted underline is a science word — tap it for a plain-English meaning.
In plain words.
HGH stands for human growth hormone. The drug version is also called somatropin. Brand names include Humatrope, Genotropin, and Norditropin.
It is a near-exact copy of the growth hormone your own pituitary gland makes. It is a chain of 191 amino acids built in a lab. Your body cannot tell it apart from the real thing.
It is for several real medical conditions. These include adults who truly lack growth hormone, kids who are not growing, and conditions like Turner syndrome and Prader-Willi.
The catch: many people use it off-label hoping it slows aging. The trial data does not support that.
What people use it for.
HGH has two very different worlds of use.
The medical world: doctors give it to people whose bodies do not make enough growth hormone. For these people, it helps body shape, energy, and (in kids) final height.
The off-label world: healthy adults take it hoping to look younger, lose fat, or build muscle. Hormone clinics sell it this way, sometimes for $1,500 a month or more. Bodybuilders use it too.
That second use is not what it was approved for, and it is the one to be careful about.
Does it actually work?
It depends entirely on who you are.
If you have a real growth hormone deficiency, yes. It improves body shape, cholesterol, and quality of life. For kids who lack it, it helps them grow.
If you are a healthy adult chasing anti-aging, the answer is no. The famous Rudman study from 1990 got people excited. But the follow-up review (Liu 2007) found the benefits were small and the side effects were real. As that review put it, the cost and side effects "are not justified by the available evidence" for healthy older adults.
what you’ve probably heard.
The claims floating around online, and how true they actually are.
“HGH turns back the clock and makes you young again.”
overblownA 1990 study got everyone excited, but the follow-up review found the gains were small and the side effects were real. For a healthy adult, the cost and risk are not justified by what it actually delivers.
“Blue-top kits are real HGH and good quality.”
mythCap color is marketing printed on counterfeit kits, nothing more. Real HGH needs a mass-spec identity check and a potency test to confirm, and gray-market pens often run 30 to 60% under-dosed.
“A clinic prescribing it for anti-aging makes it legal.”
noSelling HGH off-label is a federal crime in the U.S. under a special law, 21 USC 333(e). It is only legal for the approved conditions, which anti-aging is not.
“For someone who truly lacks it, it's life-changing.”
trueWith a documented deficiency under a hormone doctor, this is about as clear a win as peptides get. It improves body shape, cholesterol, and how people feel day to day.
How you take it.
You take it as a small shot under the skin, every day.
For approved uses, the dose is set by an endocrinologist (a hormone doctor) and kept low. A common adult dose is around 2 a day. The doctor checks your level to keep it in a safe range. IGF-1 is the growth signal HGH turns up.
This is not a once-a-week . It is a daily commitment. And for safety, it should be matched to your labs, not guessed.
What to watch out for.
The common stuff
Common side effects include carpal tunnel (numb, tingly hands), swelling and water bloat, and aching joints. These come from holding too much fluid and from the dose being too high.
The serious stuff
- It can raise blood sugar and push you toward insulin resistance over time.
- It raises , the "grow" signal that tells cells to multiply. A tumor is just cells multiplying out of control, and IGF-1 turns that dial up. Do not use it if you have an active cancer.
- It is banned by WADA in and out of sport.
- Selling HGH off-label is a federal crime in the U.S. (a special law, 21 USC 333(e), makes it illegal). This is unusual and worth knowing.
Use it only under a hormone doctor, for a documented reason. We are not your doctor, and with HGH the off-label legal risk sits right on top of the medical one.
Where people get it.
Here are the lanes, from safest to riskiest.
- Brand (Genotropin, Humatrope, Norditropin, and others). Real pharmacy product with a prescription. $1,000–$3,000 a month cash. Safest, but only legal for approved conditions.
- . Rare and tightly controlled. Often it is just brand product repackaged. $800–$1,500 a month.
- Research-only () somatropin. $200–$400 a month. Higher risk. Fakes are common.
- Gray-market overseas pens (often from China). Cheapest, but illegal to import and the biggest fake-risk channel.
Big red flag: cap color means nothing. "Blue-top" and "yellow-top" are just marketing on counterfeit kits, not a sign of quality. Real HGH is a complex biologic. A clean lab report needs both a mass-spec identity check and a potency test. Gray-market pens are often under-dosed by 30–60%.
Our honest take.
For someone whose body genuinely cannot make growth hormone, this is about as clear a win as peptides get.
A documented deficiency, or another approved condition, under an endocrinologist: get the brand, dose it to your labs, keep in range. It works, and it changes how people feel day to day.
The trouble is everyone else. If you are a healthy adult hoping it turns back the clock, the trials are simply not there. You would be paying a fortune, easily four figures a month, for water-bloated joints, a cancer worry from raised , and a federal-law problem most buyers never hear about.
And the cap-color folklore? Blue-top, yellow-top, it tells you nothing about what is in the vial. That is packaging, not proof.
The studies behind this.
We read the research so you don't have to. Here's where the facts on this page come from.
- 01Deal CL, et al. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. The Journal of clinical endocrinology and metabolism. 2022;107(7):e2717-e2728. PMID: 35405011.
- 02Thornton PS, et al. Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial. The Journal of clinical endocrinology and metabolism. 2021;106(11):3184-3195. PMID: 34272849.
- 03Webster R, et al. PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. Xenobiotica; the fate of foreign compounds in biological systems. 2008;38(10):1340-51. PMID: 18802875.
- 04Mehta A, et al. The use of somatropin (recombinant growth hormone) in children of short stature. Paediatric drugs. 2002;4(1):37-47. PMID: 11817985.
- 05Calzada-León R. [Use of recombinant Human Growth Hormone (rHGH)]. Revista medica del Instituto Mexicano del Seguro Social. 2017;55(2):196-213. PMID: 28296370.
- 06Pricci F, et al. Somatropin therapy in italian adults with growth hormone deficiency. BMC endocrine disorders. 2022;22(1):52. PMID: 35241041.
- 07Atkinson HF, et al. Effects of Recombinant Human Growth Hormone for Osteoporosis: Systematic Review and Meta-Analysis. Canadian journal on aging = La revue canadienne du vieillissement. 2017;36(1):41-54. PMID: 28069090.
- 08Phung OJ, et al. Recombinant human growth hormone in the treatment of patients with cystic fibrosis. Pediatrics. 2010;126(5):e1211-26. PMID: 20921071.
- 09Riaz M, et al. Response to Recombinant Human Growth Hormone (rhGH) Therapy in Children with Growth Hormone Deficiency. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2024;34(8):932-935. PMID: 39113512.
- 10Kamrani S, et al. Spectroscopic analysis of recombinant human growth hormone in the presence of sucrose and trehalose. Biotechnology and applied biochemistry. 2023;70(4):1543-1553. PMID: 36807340.
- 11Lamb YN. Lonapegsomatropin: Pediatric First Approval. Paediatric drugs. 2022;24(1):83-90. PMID: 34709591.
- 12Mantzoros CS, et al. Whither recombinant human growth hormone?. Annals of internal medicine. 1996;125(11):932-4. PMID: 8967675.
- 13Burgess E, et al. Use of recombinant human growth hormone in HIV-associated lipodystrophy. Current opinion in infectious diseases. 2005;18(1):17-24. PMID: 15647695.
- 14Yin MT, et al. Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity. Expert review of anti-infective therapy. 2005;3(5):727-38. PMID: 16207164.
- 15Hardin DS, et al. Twenty years of recombinant human growth hormone in children: relevance to pediatric care providers. Clinical pediatrics. 2007;46(4):279-86. PMID: 17475983.
- 16Gnacińska M, et al. Metabolic consequences of recombinant human growth hormone therapy in patients with Turner syndrome. Pediatric endocrinology, diabetes, and metabolism. 2023;29(1):16-21. PMID: 36734396.
- 17Stevens A, et al. Pharmacogenomics applied to recombinant human growth hormone responses in children with short stature. Reviews in endocrine & metabolic disorders. 2021;22(1):135-143. PMID: 33712998.
- 18Pawlikowska-Haddal A. Growth hormone therapy with norditropin ( somatropin ) in growth hormone deficiency. Expert opinion on biological therapy. 2013;13(6):927-32. PMID: 23662811.
- 19Linglart A, et al. Long-acting growth hormone in the management of GHD in France. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. 2024;31(6):357-364. PMID: 39030125.
- 20Dos Santos JBR, et al. TransCon human growth hormone for children with growth hormone deficiency: a technology evaluation. Expert opinion on drug delivery. 2022;19(1):1-7. PMID: 34996331.
- 21Chen S, et al. The Effects of Genetic Polymorphism on Treatment Response of Recombinant Human Growth Hormone. Current drug metabolism. 2018;19(14):1159-1167. PMID: 29219047.
- 22Shi Y, et al. Gonadotropin-releasing hormone analogue and recombinant human growth hormone treatment for idiopathic central precocious puberty in girls. Frontiers in endocrinology. 2022;13:1085385. PMID: 36589818.
- 23Henwood MJ, et al. Expanded spectrum of recombinant human growth hormone therapy. Current opinion in pediatrics. 2002;14(4):437-42. PMID: 12130909.
- 24Rivera-Hernández A, et al. [Somatropin and final height in Mexican paediatric population with growth hormone deficiency]. Andes pediatrica : revista Chilena de pediatria. 2022;93(4):496-503. PMID: 37906847.
- 25Saenger P. Ten years of biosimilar recombinant human growth hormone in Europe. Drug design, development and therapy. 2017;11:1505-1507. PMID: 28553081.
- 26Iglesias P, et al. Clinical applications of recombinant human growth hormone in adults. Expert opinion on pharmacotherapy. 1999;1(1):97-107. PMID: 11249568.
- 27Pan H, et al. [Safety considerations for the clinical application of recombinant human growth hormone]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. 2024;26(5):444-449. PMID: 38802902.
- 28Wanke C. Editorial comment: use of recombinant human growth hormone for wasting--questions for clinical practice. The AIDS reader. 2005;15(6):309. PMID: 15962454.
- 29Dyrka K, et al. Biological effects of recombinant human growth hormone therapy on metabolism in children with growth hormone deficiency: a review. Journal of pediatric endocrinology & metabolism : JPEM. 2025;38(8):796-806. PMID: 40320660.
- 30Deijen JB, et al. Impaired quality of life in hypopituitary adults with growth hormone deficiency : can somatropin replacement therapy help?. Treatments in endocrinology. 2006;5(4):243-50. PMID: 16879003.
- 31Chen J, et al. Polyethylene glycol recombinant human growth hormone in Chinese prepubertal slow-growing short children: doses reported in a multicenter real-world study. BMC endocrine disorders. 2022;22(1):201. PMID: 35945517.
- 32Zhang J, et al. Comparison between long-acting pegylated and daily recombinant human growth hormone for pediatric growth hormone deficiency a systematic review. Scientific reports. 2025;15(1):26746. PMID: 40702077.
- 33Svensson J, et al. Long-term efficacy and safety of somatropin for adult growth hormone deficiency. Treatments in endocrinology. 2003;2(2):109-20. PMID: 15871547.
- 34Zaky DA, et al. Recombinant human growth hormone improves the immune status of rats with septic encephalopathy: The role of VEGFR2 in the prevalence of endoplasmic reticulum stress repair module. International immunopharmacology. 2021;101(Pt B):108370. PMID: 34794887.
- 35van Dam PS. Somatropin therapy and cognitive function in adults with growth hormone deficiency : a critical review. Treatments in endocrinology. 2006;5(3):159-70. PMID: 16677058.
- 36He C, et al. Detection of doping with recombinant human growth hormone. Bioanalysis. 2009;1(5):953-65. PMID: 21083065.
- 37Iglesias P, et al. Recombinant human growth hormone therapy in adult dialysis patients. The International journal of artificial organs. 2000;23(12):802-4. PMID: 11197738.
- 38Miccoli M, et al. Height Outcome of Recombinant Human Growth Hormone Treatment in Achondroplasia Children: A Meta-Analysis. Hormone research in paediatrics. 2016;86(1):27-34. PMID: 27355624.
- 39Watson SE, et al. Recent updates on recombinant human growth hormone outcomes and adverse events. Current opinion in endocrinology, diabetes, and obesity. 2013;20(1):39-43. PMID: 23183360.
- 40Puustinen L, et al. Recombinant human growth hormone treatment after liver transplantation in childhood: the 5-year outcome. Transplantation. 2005;79(9):1241-6. PMID: 15880078.
- 41Saavedra SL, et al. Single step recombinant human growth hormone (rhGH) purification from milk by peptide affinity chromatography. Biotechnology progress. 2018;34(4):999-1005. PMID: 29693323.
- 42Geffner ME, et al. Use of recombinant human growth hormone in children with thalassemia. Hormone research. 2009;71 Suppl 1:46-50. PMID: 19153505.
- 43Zhao J, et al. Effect of recombinant human growth hormone plus vitamin D on development and lipid metabolism in children with growth hormone deficiency. Biotechnology & genetic engineering reviews. 2024;40(3):2960-2970. PMID: 37066983.
- 44Arcasoy A, et al. Recombinant human growth hormone treatment in children with thalassemia major. Pediatrics international : official journal of the Japan Pediatric Society. 1999;41(6):655-61. PMID: 10618886.
- 45Ji Y, et al. Effect analysis of recombinant human growth hormone therapy in short stature children. Panminerva medica. 2023;65(3):432-433. PMID: 34060279.
- 46Crabbé R, et al. Recombinant human growth hormone for children born small for gestational age: meta-analysis confirms the consistent dose-effect relationship on catch-up growth. Journal of endocrinological investigation. 2008;31(4):346-51. PMID: 18475054.
- 47Wolfgram PM, et al. Long-term effects of recombinant human growth hormone therapy in children with Prader-Willi syndrome. Current opinion in pediatrics. 2013;25(4):509-14. PMID: 23782572.
- 48Lee SY, et al. Structural and functional characterization of recombinant human growth hormone isolated from transgenic pig milk. PloS one. 2020;15(7):e0236788. PMID: 32735629.
- 49Loftus J, et al. Health-related quality of life in pre-pubertal children with pediatric growth hormone deficiency: 12-month results from a phase 3 clinical trial of once-weekly somatrogon versus once-daily somatropin. Current medical research and opinion. 2024;40(2):175-184. PMID: 38053515.
- 50Cheng YH, et al. Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2005;26(1):9-15. PMID: 15970435.
- 51Massart F, et al. Height outcome of the recombinant human growth hormone treatment in patients with SHOX gene haploinsufficiency: a meta-analysis. Pharmacogenomics. 2013;14(6):607-12. PMID: 23570464.
- 52Ahangari G, et al. Growth hormone antibodies formation in patients treated with recombinant human growth hormone. International journal of immunopathology and pharmacology. 2004;17(1):33-8. PMID: 15000864.
- 53Massart F, et al. Height outcome of short children with hypochondroplasia after recombinant human growth hormone treatment: a meta-analysis. Pharmacogenomics. 2015;16(17):1965-73. PMID: 26555758.
- 54Zhu F, et al. Construction and evaluation of a height prediction model for children with growth disorders treated with recombinant human growth hormone. BMC endocrine disorders. 2025;25(1):170. PMID: 40634928.
- 55Pichard C, et al. Recombinant human growth hormone in chronic and acute respiratory insufficiency. Hormone research. 1996;46(4-5):222-9. PMID: 8950625.
- 56Losada F, et al. Effects of human recombinant growth hormone on donor-site healing in burned adults. World journal of surgery. 2002;26(1):2-8. PMID: 11898025.
- 57López-Siguero JP, et al. Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data. Drug design, development and therapy. 2017;11:1489-1495. PMID: 28553079.
- 58Keating GM, et al. Somatropin (Zorbtive): in short bowel syndrome. Drugs. 2004;64(12):1375-81; discussion 1382-3. PMID: 15200350.
- 59Houdijk EC, et al. Pharmacokinetics and pharmacodynamics of recombinant human growth hormone by subcutaneous jet- or needle-injection in patients with growth hormone deficiency. Acta paediatrica (Oslo, Norway : 1992). 1997;86(12):1301-7. PMID: 9475305.
- 60Maniatis AK, et al. Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial. Hormone research in paediatrics. 2022;95(3):233-243. PMID: 35263755.
Learn about these too.
We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.
Want the rest of the peptide world, in plain English?
New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.